Pharmaceutical Care of Clinical Pharmacists on a Cancer Patient with Severe Pain

Abstract

Abstract: ObjectiveTo describe the clinical pharmacists' way in carrying out pharmaceutical care for cancer patients with severe pain. MethodsCombining with the clinical experience, make the targeted treatment scheme with the physicians together and adjust the scheme according the condition change. Pay close attentions on the patients and make reasonable suggestions as to the adverse drug reactions to guarantee the rational use of drug. ResultsClinical pharmacists can assist clinicians to adjust the therapeutic regimen from the perspective of pharmacists, and improve the level of clinical drug treatment. ConclusionPharmaceutical care on cancer patients with severe pain is needed, as it can improve the safety and rationality of taking drugs so that improve the efficacy of the treatment scheme.

Key words: cancer pain, pharmaceutical care, oral ulcer, flurbiprofen

CLC Number:

R952

ZHANG Dong-lei, WEI Qing, Tong Ben-ding, Wu Nan, Ding Xuan-sheng. Pharmaceutical Care of Clinical Pharmacists on a Cancer Patient with Severe Pain[J]. Chinese Journal of Pharmacovigilance, 2014, 11(4): 245-247.

References

[1] Davis M P,Walsh D. Epidemiology of cancer pain and factors influencing poor pain control[J]. Am J Hosp Palliat Care,2004, 21(2):137-142.
[2] NCCN.NCCN Guidelines,Adult Cancer Pain,Version 2.2012[EB/OL].(2012-09-26)[2013-10-20]http://wenku.baidu.com/view/3d3a-9d611ed9ad51f01df211.html.
[3] 章必成,姚国庆,刘健,等.氟比洛芬酯联合吗啡治疗难治性转移性骨痛[J].中国疼痛医学杂志, 2011,17(8):506-507.
[4] 冯国琴,吴平.重组人粒细胞集落刺激因子含漱液治疗鼻咽癌放疗后口腔溃疡[J].临床误诊误治,2010,23(4):356.
[5] 马新娟,崔振珠,张艳华.白血病口腔并发症的护理[J].中华护理杂志,2001, 36(8):622-623.
[6] Biswa M B. Current trends in the management of oral mucositis related to cancer treatment. Malaysian Journal of Medical Science,2008,15(3):4-13.
[7] 王秀杏,鲍婷婷,邢桂红. 特尔立漱口液用于头颈部肿瘤放化疗引起的口腔粘膜炎的观察[J]. 齐齐哈尔医学院学报, 2011,32(17):2753-2754.
[8] Chi K H, Chen C H, Chan W K, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil and leucovorin chemotherapy[J]. J Clin Oncol 1995, 13(10): 2620-2628.
[9] Wardley A M, Scarffe J H. Role of granulocyte-macrophage colony-stimulating factor in chemotherapy-induced oral mucositis[J]. J Clin Oncol, 1996, 14(5):1741-1743.
[10] Ibrahim E M, Al-Mulhim F A. Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients[J]. Med Oncol 1997,14（1）：47-51.
[11] 郦萍. 氟比洛芬酯联合芬太尼用于老年骨科患者术后镇痛对血小板活化的影响[J]. 浙江创伤外科,2012, 17(6):845-846.
[12] 米鹏程,黄莹,孔焕育,等.尖吻蝮蛇血凝酶止血作用的机制[J].中国
新药杂志,2013, 22(11):1315-1324.
[13] 兰岚,王红,刘艳华,等. 肿瘤患者PICC置管常见护理问题分析与对策[J].齐齐哈尔医学院学报,2008, 29(12)：1510-1512.
[14] Hepler C D, Strand L M. Opportunities and responsibilities in pharmaceutical care [J]. Am J Hosp Pharm, 1990,47(3):533-543.

[1]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[2]	WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin. One case of pharmaceutical care of drug exposure during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
[3]	LIU Jing, XIA Liang, ZHANG Shijie. Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
[4]	WANG Ran, FENG Xin, DU Boran. Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
[5]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[6]	YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling. Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
[7]	WANG Jiaxi, GUO Daihong, ZHANG Bo, Li Boyan, GUO Haili. Automatic monitoring and risk factors of acute kidney injury in 116097 dosing cases of flurbiprofen axetil [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 201-205.
[8]	YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang. Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
[9]	ZHENG Jinfeng, WANG Jinghong. Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.
[10]	SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying. Pharmaceutical care of a patient with indapamide-induced agranulocytosis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285.
[11]	WANG Yanting, ZHANG Yuanyuan, CHEN Yiran, SUN Jie, ZHU Yu, YANG Liyan, WU Zhigui, SHEN Lijun, CHENG Min, LI Guohui. Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1168-1172.
[12]	WANG Qiru, ZUO Li, DU Qiong, YE Ling, RUAN Cong, ZHAI Qing, XU Rui. Pharmaceutical care of a patient with grade Ⅳ myelosuppression induced by olapalil [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1176-1180.
[13]	SUN Xuelin, ZHANG Pan, HU Xin. Pharmaceutical care of a case of severe ulcerative colitis treated with vedolizumab [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 782-785.
[14]	TANG Jingya. Pharmaceutical care by a clinical pharmacists in the treatment of parenteral nutrition related hepatic damage: a case report [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 786-788.
[15]	LI Yanming, ZHAO Zhigang. Evidence-based ibrutinib-related adverse reactions and pharmaceutical care [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 807-811.